Message from the CEO
We Seek to Achieve a Sustainable Society under MISSION and VISION 30
As of April 2021, the Mitsubishi Tanabe Pharma Group has launched a new era by reconceptualizing its corporate philosophy and vision into its new MISSION and VISION 30.
MISSION and VISION 30 were developed under the same KAITEKI concept promoted by our parent company, Mitsubishi Chemical Holdings, that aims for a sustainable society and planet.
KAITEKI means “the sustainable well-being of people, society and our planet.” The Group will achieve KAITEKI through its contributions to the healthcare field.
As one of the oldest pharmaceutical companies in the world, the Mitsubishi Tanabe Pharma Group has been striving to cure diseases for more than 300 years starting with tuberculosis, hypertension, diabetes, rheumatoid arthritis, Crohn’s disease, cerebral infarction, multiple sclerosis, ALS, and other treatments, and has been creating news drugs and medications.
Looking back at what the Group has achieved so far and what Mitsubishi Tanabe Pharma should be like in the future society, in April 2021, we set for ourselves a new MISSION of “Creating hope for all facing illness” and a vision to “Be a healthcare company that delivers optimal therapy to each individual,” which VISION 30 seeks to achieve by 2030.
Today, the environment around us is dramatically changing. Thanks to digitization, online medical care, and personalized medicine, a new era will come when people facing illness have hopes beyond conventional “medicine.” This future will also open opportunities for us to do even more. We always stand in the patients’ and families’ position and deliver various solutions as well as therapeutic drugs.
To achieve our MISSION and VISION 30 in the future society, there are still things that we must value and new challenges to take on. We must value the tremendous passion and effort made to discover new drugs that has created and delivered medicines that never existed before. The challenge is to perceive society’s needs and provide healthcare solutions that improve the QOL of patients and their families, not only in drug discovery but also in prevention, pre-symptomatic disease care, and prognosis centered on therapeutic drugs. Therefore, we will also take on new collaborative challenges across industries with like-minded external partners.
The Group started Medium-Term Management Plan 21-25 from this fiscal year, and began working on precision medicine, around the pill solutions, and collecting and analyzing healthcare data. We will steadily promote these growth strategies to create hope for those facing illnesses without effective treatment.
With the changing environment and the acceleration of innovation, how will we achieve a society in which no one is left behind? The Mitsubishi Tanabe Pharma Group will conduct its management based on transparency and fairness along with its MISSION and VISION 30 with the trust of patients, their families, medical personnel, and society.
President & Representative Director
Chief Executive Officer